Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights.
Salvetti C, Vitale C, Griggio V, Drandi D, Jones R, Bonello L, Bomben R, Bragoni A, Bagnara D, Fais F, Gattei V, Cavallo F, Zamò A, Coscia M. Salvetti C, et al. Among authors: coscia m. Front Oncol. 2022 Jun 6;12:917115. doi: 10.3389/fonc.2022.917115. eCollection 2022. Front Oncol. 2022. PMID: 35734588 Free PMC article.
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.
Coscia M, Vitale C, Peola S, Foglietta M, Rigoni M, Griggio V, Castella B, Angelini D, Chiaretti S, Riganti C, Guarini A, Drandi D, Ladetto M, Bosia A, Foà R, Battistini L, Boccadoro M, Fournié JJ, Massaia M. Coscia M, et al. Blood. 2012 Oct 18;120(16):3271-9. doi: 10.1182/blood-2012-03-417519. Epub 2012 Aug 29. Blood. 2012. PMID: 22932792 Free article.
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G. Rossi D, et al. Among authors: coscia m. Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14. Blood. 2015. PMID: 26276669 Free PMC article. Clinical Trial.
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.
Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M, Coscia M. Rigoni M, et al. Among authors: coscia m. Oncotarget. 2015 Oct 6;6(30):29833-46. doi: 10.18632/oncotarget.4006. Oncotarget. 2015. PMID: 26284584 Free PMC article.
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.
Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C, Ferracini R, Saraci E, Omedé P, Riganti C, Palumbo A, Boccadoro M, Massaia M. Castella B, et al. Among authors: coscia m. Oncoimmunology. 2015 May 26;4(11):e1047580. doi: 10.1080/2162402X.2015.1047580. eCollection 2015 Nov. Oncoimmunology. 2015. PMID: 26451323 Free PMC article.
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.
Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra S, Castella B, Peola S, Foglietta M, Drandi D, Omedé P, Sblattero D, Cappello P, Chiarle R, Deaglio S, Boccadoro M, Novelli F, Massaia M, Coscia M. Griggio V, et al. Among authors: coscia m. Oncotarget. 2017 Jan 10;8(2):3274-3288. doi: 10.18632/oncotarget.13712. Oncotarget. 2017. PMID: 27906678 Free PMC article.
281 results